Vanda Pharmaceuticals (NASDAQ:VNDA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis [Yahoo! Finance]
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness [Yahoo! Finance]